EODData

SHE, 300142: Walvax BioTech

23 Oct 2026
LAST:

12.70

CHANGE:
 0.24
OPEN:
12.25
HIGH:
12.74
ASK:
0.00
VOLUME:
64.66M
CHG(%):
1.93
PREV:
12.46
LOW:
11.98
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Oct 2612.2512.7411.9812.7064.66M
22 Oct 2612.9013.0012.4612.4646.64M
21 Oct 2613.0813.2512.9012.9445.64M
20 Oct 2612.7512.9712.6012.9245.06M
19 Oct 2613.0013.1512.6612.8567.32M
16 Oct 2613.4013.7913.1013.2777.19M
15 Oct 2613.2613.7913.2013.2073.44M
14 Oct 2613.9013.9113.3013.3581.19M
13 Oct 2613.8914.2313.7714.0880.27M
12 Oct 2614.7514.9614.0214.05105.16M

PROFILE

Name:Walvax BioTech
About:Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
Sector:Healthcare
Address:No. 395 Kexin Road, Kunming, China, 650101
Website:https://www.walvax.com
ISIN:CNE100000WN2

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:111.25 
Forward P/E:29.67 
PEG Ratio:29.67 
Price to Sales:10.18 
Price to Book:3.06 
Profit Margin:0.09 
Operating Margin:-0.07 
Return on Assets:0.01 
Return on Equity:0.02 
DivYield:0.00 
Div/Share:0.01 
Revenue:2.098B 
EBITDA:271.56M 
Shares:1.599B 
Market Cap:20.312B 

TECHNICAL INDICATORS

MA5:12.770.6%
MA10:13.183.8%
MA20:13.536.6%
MA50:13.597.0%
MA100:13.052.8%
MA200:12.770.5%
STO9:13.56 
STO14:9.45 
RSI14:40.17
WPR14:-89.52 
MTM14:-0.79
ROC14:-0.06 
ATR:0.71 
Week High:13.798.6%
Week Low:11.986.0%
Month High:15.0018.1%
Month Low:11.980.5%
Year High:16.9733.6%
Year Low:10.8816.7%

RECENT SPLITS

Date Ratio
14 Oct 201530-10
23 Apr 201520-10
30 May 201413-10
07 May 201212-10
05 May 201115-10

RECENT DIVIDENDS

Date Amount
24 Jun 2026$0.13
09 Jan 2026$0.03
28 May 2025$0.01
30 May 2024$0.01
11 May 2023$0.01
26 Apr 2022$0.03
19 May 2021$0.05
30 Sep 2020$0.02
23 Jul 2019$0.03
23 Apr 2015$0.00